Please login to the form below

Not currently logged in

Roche acquires test maker TIB Molbiol

The Swiss biopharmaceutical group has acquired the Berlin-based diagnostics biotech after two decades of collaboration, expanding its PCR test portfolio


There was a time when few non-scientists had heard of PCR (polymerase chain reaction) tests but now, in the age of COVID-19, the term has entered everyday language.

As another sign of its importance, Roche has acquired its long-term partner, diagnostics company TIB Molbiol in order to expand its test portfolio and bolster ‘the fight against new infectious diseases’.

Roche announced its intention to acquire the company in September and has now completed its share purchase agreement, acquiring all of TIB Molbiol Group’s outstanding shares.

The company will operate under the Roche umbrella as a subsidiary of the Diagnostics division, adding its 45+ CE-marked in vitro diagnostics assays and 100+ research-use assays to the Roche portfolio.

The two companies have collaborated for more than 20 years ‘to rapidly address critical healthcare needs including biological threats’ that include SARS, anthrax, avian influenza virus H5N1, MERS, the novel influenza virus H1N1 swine, Ebola virus, Zika virus and most recently, SARS-CoV-2 virus and its variants, said Roche.

“I am very pleased that together with TIB Molbiol, we can significantly improve access for patients to a broader spectrum of diagnostic tests – from high volume routine tests to the diagnosis of rare diseases,” said Thomas Schinecker, head of Roche Diagnostics. “TIB Molbiol will continue to be an innovation engine and frontrunner in our common fight against infectious diseases, such as SARS-CoV-2.”

For more than 30 years TIB Molbiol has supplied reagents for research and medical diagnostics including custom oligonucleotides with which the company partnered in the development of molecular diagnostics. The resulting broad portfolio of diagnostic assays covers inherited genetic as well as somatic mutation testing, quantitative assays for haematology and transplantation medicine.

However, the company’s greatest focus has been on assays to test for infectious diseases. Its assays are available as modular kits that allow ‘symptomatic panels’ to be created by combining assays, which is especially valuable when faced with emerging pathogens.

TIB Molbiol’s ultra-rapid assay development for emerging infectious diseases has been demonstrated against both SARS-CoV-1 – when it developed an assay within days in 2003 – and SARS-CoV-2.

Article by
Hugh Gosling

2nd December 2021

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
Hybrid working: Insights and tips for success
Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success...
The doctor will text you now: Why healthcare providers cannot underestimate the importance of communicating change
Healthcare communication needs to switch from ‘transmit’ to ‘receive’, listening to what patients need and embracing the plethora of communication tools wholeheartedly....